{"analyses":[{"ciLowerLimit":"0.683","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.188","groupDescription":"Teff high-WT ITT","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4599","paramType":"Hazard Ratio (HR)","paramValue":"0.901","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.6","upperLimit":"26.3","value":"21.3"},{"groupId":"OG001","lowerLimit":"19.1","upperLimit":"32.6","value":"25.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"156"}],"units":"Participants"}],"title":"Teff High-WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.7","upperLimit":"21.5","value":"19.0"},{"groupId":"OG001","lowerLimit":"17.0","upperLimit":"22.2","value":"19.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"350"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"ITT-WT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"350"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG001","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.","reportingStatus":"POSTED","timeFrame":"Baseline until death (up approximately 53 months)","title":"OS in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population","type":"SECONDARY","unitOfMeasure":"Months"}